F rom the beginning of the HIV epidemic, for many years, data were insufficient to answer the question: how many infants with HIV infection are born annually in the United States? Until recently, therefore, it has been necessary to estimate that number by modeling or other means.
Since the mid-1980s, AIDS reporting was mandatory in nearly all jurisdictions, whereas name-based reporting of cases of HIV infection was conducted in a subset of states. Not until 2008 had all states implemented name-based reporting, and only when the systems in all jurisdictions had "matured" sufficiently, in 2012, were the data made available for all the United States. Specifically, since 2008, it has been possible to determine the number of infants born with HIV infection in the United States. With these numbers, it has become possible to calculate the incidence of perinatally acquired HIV, thus addressing one of the goals of the Centers for Disease Control and Prevention for the elimination of perinatally acquired HIV, 1 namely, an incidence less than 1 per 100,000 live births.
Before 2008, there were several estimates of the number of infants born with HIV infection in all 50 states. [2] [3] [4] [5] For the earliest years of the epidemic (1978) (1979) (1980) (1981) (1982) (1983) (1984) (1985) (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) , the number was "back calculated," 2 beginning with the number of infants and children with diagnoses of AIDS. In more recent years, the number of infants born with HIV infection in the United States was determined by Taylor et al 6 for the years 2006-2009, accounting for 2 types of delay-birth to diagnosis and diagnosis to report-but had to extrapolate from the states with name-based reporting to the rest of the states; this number is considered "estimated" because it incorporates those 2 weights. These estimated numbers [2] [3] [4] [5] [6] were used to construct a curve representing the estimated annual number of infants with HIV infection born during 1978-2010 7 ; in that report, for years in which no estimate had been made, the numbers of infants with HIV infection were interpolated. A subsequent report 8 estimated the numbers of infants with HIV infection for 2002-2013; this report accounted for delays from birth to diagnosis and from diagnosis to report as had been done earlier 6 but did not require extrapolation from states which did not have name-based reporting-an improvement over the former method.
To calculate estimated incidence rates of perinatally acquired HIV infection for 1978-2013 (ie, the number of infants per 100,000 live births), the numbers of infants with perinatal HIV infection estimated for 1978-1993, 2 1995-1996, 3 2000, 4 and 2002-2013 8 and the interpolated numbers between those years were divided by the respective annual number of live-born infants in the United States. 9 Table 1 shows the annual numbers of live-born infants in the United States, the estimated annual number of infants with perinatal HIV born in the United States, and the incidence of perinatal HIV per 100,000 live births with exact 95% confidence intervals (CIs) calculated using the Poisson distribution. The incidence per 100,000 live births is depicted graphically in Figure 1 and fit with a cubic smoothing spline.
From Figure 1 , several observations are possible. Peak estimated incidence occurred in 1992, with 43.1 per 100,000 live births (95% CI: 41.1 to 45.1). Overall, since the implementation of antiretroviral prophylaxis to prevent mother-to-child HIV transmission, 10 that is, during 1994-2013, the incidence of perinatally acquired HIV in the United States has decreased approximately 94%. There is an approximately 96% decrease from the peak, which was reached in 1992 several years before the 1994 recommendation to use zidovudine prophylaxis for pregnant women with HIV infection and their newborn infants. 10 The incidence of HIV infection in infants declined rapidly in a brief period once zidovudine prophylaxis became standard, a 71% decrease by 1996. That is, a large proportion of the overall decrease occurred in the period when most, if not all, perinatal prophylaxis regimens used a single drug, zidovudine.
In the years immediately after the initial large decrease, 2 major interventions were introduced. The first was the use of 3-drug antiretroviral regimens (known then as "highly active antiretroviral therapy," or HAART, known for a while as "combination antiretroviral therapy" or cART; now simply known as antiretroviral therapy, ART). 11 Although the recommendations did not specify whether such therapy should continue after pregnancy, by 1998, nearly half of women who began ART during pregnancy continued postpartum, 12, 13 with higher percentages in the years immediately after. 14, 15 The second major intervention was the introduction of scheduled cesarean delivery for pregnant women with HIV infection whose plasma levels of HIV ("viral load") were not well controlled. [16] [17] [18] During 2002-2007, although there was still no specific recommendation to continue ART postpartum, it seems that the practice was becoming more common. 15 In the subsequent period, new antiretroviral drugs were introduced and became components of preferred or alternative regimens for HIV-infected pregnant women. Tenofovir and darunavir were recommended for alternative regimens in 2012, 19 which also included raltegravir for special circumstances. "Preferred" regimens recommended in 2014 20 and 2016, 21 respectively, included tenofovir and raltegravir, reflecting increased use of such regimens in the years immediately preceding. In addition, in 2012 (March 27), treatment guidelines for adults recommended unequivocally that ART should be started for all HIV-infected persons and should not be discontinued. 22 Concurrent with this change in practice, between 2007 and 2013, there was a 64% decline in the incidence of perinatally acquired HIV infections in the United States. During this period, the proportion of pregnant women with HIV infection receiving an integrase strand inhibitor as part of their regimen appears to have increased dramatically; in 2015, 43% of pregnant women enrolled in the Perinatal HIV/AIDS Cohort Study were receiving an integrase strand inhibitor as a component of their ART (20% dolutegravir, 20% elvitegravir, and 3% raltegravir). 23 The lowest estimated incidence of perinatally acquired HIV was in 2013, with 1.8 per 100,000 live births (95% CI: 53.7 to 87.3), still lower than CDC's incidence goal.
Perinatal HIV transmission continues to occur in the United States, for well-recognized reasons: late maternal diagnosis and incomplete uptake of ART. 8 Despite these factors, we describe here a continued-albeit protracteddecline in the incidence curve of perinatally acquired HIV infection. The degree that this curve is affected by the numbers of women of childbearing age is undetermined, but it is interesting that the number of women of childbearing age (13-44 years) living with HIV declined approximately 10% during 2008-2014, 24 and the number of new diagnoses of women in this age range declined approximately 30%. 25 There is reason to believe that the number of births to women living with HIV has declined significantly in recent years. 26 The relative impact of these declines, the apparently increasing birth rate among women living with HIV, 27 and the dramatic increase in the use of more potent antiretroviral therapy with integrase inhibitors-with their improved tolerability and ability to rapidly reduce HIV viral load-have yet to be determined. 
